This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Uchiyama, S. Articles by Hirosawa, K. Search for Related Content PubMed PubMed Citation Articles by Uchiyama, S. Articles by Hirosawa, K.

Stroke, Vol 14, 511-517, Copyright © 1983 by American Heart Association

ARTICLES

Platelet function tests in thrombotic cerebrovascular disorders

S Uchiyama, M Takeuchi, M Osawa, I Kobayashi, S Maruyama, M Aosaki and K Hirosawa

A variety of platelet function tests were performed in patients with four forms of obstructive cerebrovascular disease (CVD); transient ischemic attacks (TIA), reversible ischemic neurological deficit (RIND), cerebral infarct, and cerebral embolism of cardiac source in rheumatic valvular heart disease (RVHD). Platelet studies included platelet aggregation induced by ADP and ristocetin, spontaneous platelet aggregation, von Willebrand factor (VIII:vWF), platelet aggregation enhancing factor (PAEF), and percentage of large platelets (megathrombocytes). Serial testing was carried out in acute stroke patients. The effect of aspirin therapy was also evaluated. A clear difference in results was observed between patients with cardiogenic embolism and those with other forms of CVD. In patients with TIA, RIND, and cerebral infarct, platelet aggregation, both induced and spontaneous, was enhanced along with elevation of plasma VIII:vWF and PAEF, and increased percentage of megathrombocytes. In patients with cardiogenic embolism, however, these studies were negative except for percent megathrombocytes. This value was increased in the embolic patients with RVHD in comparison with non-embolic patients with RVHD. Increase in platelet aggregation to ADP and percent megathrombocytes developed slowly over a week following stroke. Induced and spontaneous platelet aggregation, and percent megathrombocytes could be normalized with 600 mg aspirin p.o. These studies suggest that a systemic increase of hyperaggregable platelets and of plasma activators of platelet function exists in thrombotic CVD and may be related to its pathogenesis, while local hemodynamic factors may be more important in the thrombogenesis of cardiogenic embolism.

This article has been cited by other articles:

				S. Hascelik, D. Yalnzoglu, G. Kafali, A. Celiker, A. Cila, M. Topcu, and A. Gurgey Stroke Owing to Noncompaction of Myocardium J Child Neurol, June 1, 2003; 18(6): 437 - 439. [Abstract] [PDF]

				A. M. Carter, A. J. Catto, J. M. Bamford, and P. J. Grant Association of the Platelet Glycoprotein IIb HPA-3 Polymorphism With Survival After Acute Ischemic Stroke Stroke, December 1, 1999; 30(12): 2606 - 2611. [Abstract] [Full Text] [PDF]

				N. M Smith, R. Pathansali, and P. M. Bath Platelets and stroke Vascular Medicine, August 1, 1999; 4(3): 165 - 172. [Abstract] [PDF]

				W. P. Hammond, T. Wun, A. Kaplan, S. Kaplan, T. Paglieroni, K. Kaushansky, and D. C. Foster High Concentrations of Thrombopoietin Activate Platelets In Vitro Clinical and Applied Thrombosis/Hemostasis, July 1, 1998; 4(3): 170 - 178. [Abstract] [PDF]

				A. M. Carter, A. J. Catto, J. M. Bamford, and P. J. Grant Platelet GP IIIa PlA and GP Ib Variable Number Tandem Repeat Polymorphisms and Markers of Platelet Activation in Acute Stroke Arterioscler. Thromb. Vasc. Biol., July 1, 1998; 18(7): 1124 - 1131. [Abstract] [Full Text] [PDF]

				E. F. Mammen Ten Years' Experience with the "Sticky Platelet Syndrome" Clinical and Applied Thrombosis/Hemostasis, January 1, 1995; 1(1): 66 - 72. [Abstract] [PDF]

				G. Lippi, G. Arnetoli, R. Accardi, and A. Doni Hemostatic Balance Index in TIA Patients: Sex-Related Changes Angiology, July 1, 1985; 36(7): 425 - 430. [Abstract] [PDF]